

Filed On Behalf Of: Novartis AG

By: Nicholas N. Kallas  
NKallas@fchs.com  
ZortressAfinitorIPR@fchs.com  
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

**PAR PHARMACEUTICAL, INC.,  
BRECKENRIDGE PHARMACEUTICAL, INC., AND  
ROXANE LABORATORIES, INC.,**

Petitioners,

v.

**NOVARTIS AG,**  
Patent Owner.

---

Case IPR2016-00084<sup>1</sup>  
Patent 5,665,772

---

**SECOND UPDATE TO PATENT OWNER'S MANDATORY NOTICES  
UNDER 37 C.F.R. § 42.8(a)(3)**

---

<sup>1</sup> Breckenridge Pharmaceutical, Inc. was joined as a party to this proceeding via a Motion for Joinder in IPR2016-01023; Roxane Laboratories, Inc. was joined as a party via a Motion for Joinder in IPR2016-01102.

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(3), Novartis AG (“Novartis” or “Patent Owner”) submits the following update to its November 13, 2015 Mandatory Notices (Paper No. 5) as amended by its July 12, 2016 Updated Mandatory Notices (Paper No. 23).

**REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)**

The real party-in-interest information has not changed.

**RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)**

The related matters information has not changed.

**IDENTIFICATION OF LEAD AND BACK-UP COUNSEL  
PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10**

The lead counsel information has not changed.

The Patent Owner hereby notifies the Board that it is removing back-up counsel Raymond R. Mandra (Reg. No. 34,382) and adding attorney of record Charlotte Jacobsen (admitted *pro hac vice*) as additional back-up counsel, as shown below. All other counsel information remains the same.

<b>Lead Counsel</b>	<b>Back-Up Counsel</b>
Nicholas N. Kallas FITZPATRICK, CELLA, HARPER & SCINTO 1290 Avenue of the Americas New York, NY 10104 -3800 Tel. 212-218-2100 nkallas@fchs.com	Christina Schwarz ( <i>pro hac vice</i> ) FITZPATRICK, CELLA, HARPER & SCINTO 1290 Avenue of the Americas New York, NY 10104-3800 Tel. 212-218-2100 cschwarz@fchs.com

Additional Back-Up Counsel	Additional Back-Up Counsel
Peter J. Waibel (Registration No. 43,228) NOVARTIS PHARMACEUTICALS CORPORATION One Health Plaza, Bldg. 430 East Hanover, NJ 07936-1080 Tel. 862-778-7838	Charlotte Jacobsen ( <i>pro hac vice</i> ) FITZPATRICK, CELLA, HARPER & SCINTO 1290 Avenue of the Americas New York, NY 10104-3800 Tel. 212-218-2100 cjacobsen@fchs.com

A power of attorney designating Charlotte Jacobsen was filed on November 3, 2016 (Paper No. 42).

**SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)**

The service information has not changed.

Respectfully submitted,

Dated: January 26, 2017

/ Nicholas N. Kallas /  
 Nicholas N. Kallas  
 Registration No. 31,530  
 Lead Counsel for Patent Owner  
 FITZPATRICK, CELLA, HARPER  
 & SCINTO  
 1290 Avenue of the Americas  
 New York, NY 10104-3800  
 Tel. 212-218-2100

## CERTIFICATE OF SERVICE

I certify that a copy of the Second Update To Patent Owner's Mandatory Notices Under 37 C.F.R. § 42.8(a)(3) was served on January 26, 2017 by causing it to be sent by email to counsel for Petitioners at the following email addresses:

Daniel G. Brown (dan.brown@lw.com)

Robert Steinberg (bob.steinberg@lw.com)

Brenda L. Danek (Brenda.danek@lw.com)

Jonathan M. Strang (jonathan.strang@lw.com)

Matthew L. Fedowitz (mfedowitz@merchantgould.com)

B. Jefferson Boggs (jboggs@merchantgould.com)

Daniel R. Evans (devans@merchantgould.com)

Keith A. Zullo (kzullo@goodwinlaw.com)

Marta Delsignore (mdelsignore@goodwinprocter.com)

Dated: January 26, 2017

/ Nicholas N. Kallas /  
Nicholas N. Kallas  
Registration No. 31,530  
Lead Counsel for Patent Owner  
FITZPATRICK, CELLA, HARPER  
& SCINTO  
1290 Avenue of the Americas  
New York, NY 10104-3800  
Tel. 212-218-2100